Compare AbbVie Inc (ABBV) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Cognizant Technology Solutions Corp — how do they compare? AbbVie Inc trades at $248.6 (market cap $438.19B), while Cognizant Technology Solutions Corp trades at $58.53 (market cap $26.27B). The key difference: AbbVie Inc is far larger — about 16.7× Cognizant Technology Solutions Corp's market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | CTSH | |
|---|---|---|
Market Cap | $438.19B | $26.27B |
Sector | Health | Technology |
52-Week High | $263.58 | $86.70 |
52-Week Low | $197.38 | $38.73 |
Enterprise Value | $502.45B | $27.31B |
Dividend Yield | 2.79% | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.91, up 1.57% on the day, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $3.87. Revenue growth is robust, projected at $64.4B for 2026, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive clinical trial results for ELAHERE® and institutional buying activity underscore momentum.
The outlook remains positive given earnings beats, a 70.73% buy rating from analysts, and a $281.33 consensus price target. Key risks include patent expirations in the 2030s, high debt levels, and margin pressure. The dividend yield adds income appeal, but execution on pipeline products is critical for sustained growth.
CTSH trades at $57.67, up 1.37% with a bullish technical signal. Recent Q2 2026 earnings missed EPS estimates at $1.37 versus $1.38 expected, though revenues beat. The company maintains solid fundamentals with a P/E of 12.37 and ROE of 14.92%, supported by strong cash flow from operations of $2.88B in 2025. AI initiatives, including the new EMEA AI Unit, highlight growth efforts amid cautious client spending.
Outlook is mixed: valuation appears attractive with upside to the $59.92 consensus target, but risks include macroeconomic pressures on IT spending and competitive disruption from AI. Earnings consistency and AI adoption execution are critical for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
